GLP-1 Therapies Newsletter
Issue #36May 11, 20267 studies

Tirzepatide beats semaglutide for weight loss: 8.2% vs 5.8% body weight reduction at 12 months

The GLP-1 weight loss drug wars just got more interesting. New research is revealing which medications work best, how they affect the brain, and what happens when people stop taking them.

🥇 Head-to-Head: Tirzepatide Outperforms Semaglutide for Weight Loss

  • 60,198 patients with rheumatic diseases lost more weight on tirzepatide than semaglutide: 8.2% vs 5.8% body weight reduction at 12 months

  • Tirzepatide users were 2.2 percentage points more likely to achieve meaningful weight loss compared to semaglutide users

  • Patients without diabetes saw even better results, losing 1.8% more body weight than those with diabetes on either medication

Why it matters: This real-world data confirms tirzepatide's superior weight loss effects seen in clinical trials, giving doctors clearer guidance on which GLP-1 medication to prescribe for maximum weight reduction.

Top 20% journal 🔗 ACR open rheumatology Journal Article 🗓️ May 8

Key Findings

🧠 GLP-1 Drugs Target Brain Reward Circuits in Mice

  • Researchers using humanized mouse models discovered GLP-1 drugs activate specific neurons in the brain's central amygdala

  • These neurons selectively reduce consumption of palatable foods by decreasing dopamine release in the brain's reward center

  • When scientists deleted GLP-1 receptors in this brain region, the drugs lost their ability to reduce reward-driven eating

💡 This brain circuit discovery may explain why GLP-1 drugs reduce cravings for high-calorie foods beyond just slowing digestion.
🔗 Nature Journal Article 🗓️ May 6

💊 Stopping GLP-1 Drugs Before Pregnancy Linked to Higher Diabetes Risk

  • 892 women who stopped GLP-1 drugs abruptly (within 90 days of conception) had 53% higher risk of gestational diabetes compared to those who never used the drugs

  • Women who stopped the medications 6-18 months before pregnancy had normal gestational diabetes rates, despite modest weight regain

  • The timing of discontinuation, not the prior drug exposure itself, determined diabetes risk during pregnancy

💡 The post-withdrawal window and speed of weight rebound may be more important than the medication history itself for pregnancy outcomes.
🔗 Diabetes, obesity & metabolism Journal Article 🗓️ May 7

🔬 GLP-1 Drugs May Not Help Alzheimer's or Parkinson's

  • Meta-analysis of 1,260 non-diabetic patients found GLP-1 drugs produced only trivial cognitive improvements with just 1% probability of clinically meaningful benefit

  • Patients actually performed worse on verbal fluency tests while taking the medications

  • Despite statistical significance in some measures, the improvements fell below thresholds considered clinically important for patients

💡 Current evidence doesn't support GLP-1 drugs as treatments for brain diseases, despite promising early theories about their neuroprotective effects.
🎖️ Top 10% journal 🔗 Archives of pharmacal research Review 🗓️ May 7

⚠️ Gastric Emptying Delays Create Surgery Risks

  • Meta-analysis of 300 patients showed GLP-1 drugs slow stomach emptying by an average of 74 minutes

  • Short-acting versions caused even longer delays (116 minutes) and effects were strongest in early treatment phases under 10 weeks

  • The delayed gastric emptying increases aspiration risk during airway surgeries, though specific guidelines for ENT procedures remain inconsistent

💡 Surgeons need individualized approaches for patients on GLP-1 drugs, especially for airway procedures where aspiration poses serious risks.
Top 20% journal 🔗 Canadian journal of anaesthesia = Journal canadien d'anesthesie Journal Article 🗓️ May 5

🎯 Predictors of Poor Response Identified

  • Higher baseline body weight, BMI, blood sugar levels, and insulin resistance all predict worse weight loss outcomes on GLP-1 drugs

  • Genetic variants in the GLP-1 receptor gene may influence treatment success

  • Male sex, older age, and poor medication adherence are also linked to reduced weight loss responses

💡 Understanding who responds poorly could help doctors set realistic expectations and potentially adjust treatment strategies from the start.
🔗 Obes Rev Review 🗓️ May 5

💰 Cost-Effectiveness Confirmed for Liver Disease

  • Economic analysis of 782,920 obese Italian adults with liver disease found semaglutide 2.4mg cost €22,691 per quality-adjusted life year gained

  • This falls below Italy's accepted cost-effectiveness thresholds for healthcare interventions

  • The analysis factored in both liver disease progression prevention and obesity-related complication reductions over 10 years

💡 GLP-1 drugs may offer good value for healthcare systems when targeting high-risk patients with both obesity and liver disease.
Top 30% journal 🔗 ClinicoEconomics and outcomes research : CEOR Journal Article 🗓️ May 8

Implications

The GLP-1 drug landscape is rapidly evolving beyond simple weight loss. While tirzepatide shows superior efficacy and these medications prove cost-effective for certain conditions, the research reveals important limitations—from brain disease applications to surgery risks—that will shape how doctors prescribe them. The key seems to be matching the right drug to the right patient at the right time.

Studies in this issue

Primary sources used for this newsletter.

  1. Patterns of Starting Semaglutide and Tirzepatide and Their Link to Weight Loss in Rheumatic and Musculoskeletal Diseases
    main storyACR open rheumatology2026-05-08PMID 42101387
  2. Clinical benefits of GLP-1 receptor drugs for Alzheimer's and Parkinson's diseases measured by meaningful improvement
    key findingArchives of pharmacal research2026-05-07PMID 42098470
  3. Cost-effectiveness of 2.4 mg Semaglutide for Obese Patients with Fatty Liver Disease in Italy's Health System
    key findingClinicoEconomics and outcomes research : CEOR2026-05-08PMID 42099530
  4. Glucagon-like peptide-1 receptor agonists and their effects on stomach emptying time: a review and analysis of prospective studies
    key findingCanadian journal of anaesthesia = Journal canadien d'anesthesie2026-05-05PMID 42087044
  5. Low Weight Loss with Incretin-Based Medicines: A Systematic Review
    key findingObesity reviews : an official journal of the International Association for the Study of Obesity2026-05-05PMID 42083728
  6. A brain reward system reduced by new weight-loss drugs in mice
    key findingNature2026-05-06PMID 42092139
  7. Use of GLP-1 Receptor Agonists or Tirzepatide Before Pregnancy and Risk of Gestational Diabetes: Comparing Lasting Drug Effects and Metabolic Changes After Stopping
    key findingDiabetes, obesity & metabolism2026-05-07PMID 42098901

Continue reading

All GLP-1 Therapies issues